Loading...
Market
Average annual cost of ATTR-CM treatments in US by Dec 31, 2025?
2
Resolution / Starting Odds
Below $200,000 • 25%
$200,000 - $250,000 • 25%
$250,001 - $300,000 • 25%
Above $300,000 • 25%
Healthcare pricing reports and company announcements
Story
FDA Approves BridgeBio's Attruby (Acoramidis), First Near-Complete TTR Stabilizer for ATTR-CM
Nov 23, 2024, 12:14 AM
BridgeBio Pharma (ticker symbol $BBIO) announced that the U.S. Food and Drug Administration (FDA) has approved Attruby™ (acoramidis), an orally administered near-complete transthyretin (TTR) stabilizer for the treatment of adult patients with transthyretin cardiac amyloidosis (ATTR-CM). Attruby, the first and only approved product specifying near-complete stabilization of TTR (≥90%), was designed to mimic a naturally occurring 'rescue mutation' of the TTR gene (T119M), targeting the root cause of ATTR-CM by preventing destabilization of the native TTR tetramer. The drug is approved to reduce cardiovascular death and cardiovascular-related hospitalization in ATTR-CM patients. The approval sets up competition with Pfizer, which also markets a treatment for ATTR-CM. Attruby will be priced at approximately $245,000 per year.
View original story
Similar markets
Less than £1000 • 25%
£1000 to £2000 • 25%
£2001 to £3000 • 25%
More than £3000 • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than $500,000 • 25%
$500,000 to $750,000 • 25%
$750,000 to $1,000,000 • 25%
More than $1,000,000 • 25%
Yes • 50%
No • 50%
Less than 10% • 25%
10%-20% • 25%
20%-30% • 25%
More than 30% • 25%
Phase 2 Trial Completion • 25%
FDA Approval • 25%
Commercial Launch • 25%
None of the Above • 25%
Less than $10 billion • 25%
$10 billion to $20 billion • 25%
$20 billion to $30 billion • 25%
More than $30 billion • 25%
Revenue decrease due to MRT-6160 • 25%
Revenue increase due to MRT-6160 • 25%
No significant financial impact • 25%
MRT-6160 discontinued • 25%
Less than 100 patients • 25%
100 to 500 patients • 25%
501 to 1000 patients • 25%
More than 1000 patients • 25%
Less than 100 • 25%
100 - 500 • 25%
500 - 1000 • 25%
More than 1000 • 25%
Less than $200 million • 25%
$200 million to $400 million • 25%
$400 million to $600 million • 25%
More than $600 million • 25%